Health physicists are establishing safe procedures for a promising experimental brain-cancer therapy which uses a radioactive version of a protein found in scorpion venom. For many, this will conjure images of Spiderman's nemesis, the Scorpion. The purpose of this work is not science fiction, but rather to help to develop a promising new therapy for brain cancer. The venom of the yellow Israeli scorpion preferentially attaches to the cells of a type of essentially incurable brain cancers known as gliomas.
Responding to this urgent problem, scientists at the Transmolecular Corporation in Cambridge, Massachusetts created a radioactive version of this scorpion venom. Called TM-601, it contains an artificial version of the venom protein, attached to a radioactive substance called iodine-131 (I-131). When it enters the bloodstream, the compound attaches to the glioma cells, then the I-131 releases radiation that kills the cell.
This compound has enabled an experimental treatment for high-grade gliomas, found in 17,000 people in the US every year and usually causing death in the first year of diagnosis. Patients would simply be injected with the compound in an outpatient procedure, without needing chemotherapy or traditional radiotherapy. The first, early human trials of the venom therapy showed promising signs for treating the tumor and prolonging survival rates for patients.
At the Health Physics Society meeting this week in Providence, Rhode Island, Alan M. Jackson of the Henry Ford Health System in Detroit will report that he and his colleagues recently established safe procedures for the therapy, currently in the second sequence of phase-II human trials, which involve higher doses of radiation than the earliest trials.
"The health physicist has the duty to ensure to ensure that these therapies are conducted both legally and safely," Jackson says. "Obviously, a key objective is to bring these patients home and to ensure that their loved ones and the environment are properly protected."
In the trials, one group of patients received the therapy three times over three weeks, while the other group received the therapy 6 times over 6 weeks. Each group received the same dose of radioactive iodine per week, 40 millicuries (mCi). According to Jackson, this is not tremendously high compared to a thyroid cancer treatment, in which patients receive up to 200 mCi in a single treatment.
As Jackson discovered, the TM-601 that does not bind to cells in the body is rapidly excreted in the urine. "Other tissues will receive some dose," he says, "but the vast majority of the dose is delivered to the cancer cells." To prevent the radioactive compound from being absorbed by the thyroid, which has a voracious appetite for iodine, the patients were given large amounts of non-radioactive iodine prior to the therapy to block the thyroid uptake of I-131.
When the patient returns home several hours after the procedure, there are radiation doses to any family members at home due to the presence of radiation in the patient's body. Such radiation exposures to family members, Jackson found, are low and comparable to those from a family member receiving standard thyroid cancer therapy.
Jackson is encouraged by the safety of this procedure and its potential to help patients with brain gliomas. A recent study of the earlier phase II trials showed that patients receiving up to 40 mCi of weekly dose did not show evidence of any adverse reactions attributable to the radiation. The second-sequence phase II trial at Henry Ford involves 3 patients, with a total of 54 patients across the US currently in investigational trials for the therapy.
Kelly Classic | EurekAlert!
NASA spacecraft investigate clues in radiation belts
28.03.2017 | NASA/Goddard Space Flight Center
Researchers create artificial materials atom-by-atom
28.03.2017 | Aalto University
The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.
To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
28.03.2017 | Life Sciences
28.03.2017 | Information Technology
28.03.2017 | Physics and Astronomy